[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Innoviva Inc (INVA)

Innoviva Inc (INVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,668,821
  • Shares Outstanding, K 73,809
  • Annual Sales, $ 411,330 K
  • Annual Income, $ 271,170 K
  • EBIT $ 154 M
  • EBITDA $ 196 M
  • 60-Month Beta 0.35
  • Price/Sales 4.02
  • Price/Cash Flow 4.46
  • Price/Book 1.23

Options Overview Details

View History
  • Implied Volatility 29.11% (-43.88%)
  • Historical Volatility 24.74%
  • IV Percentile 1%
  • IV Rank 0.88%
  • IV High 184.90% on 01/16/26
  • IV Low 27.73% on 05/08/26
  • Expected Move (DTE 29) 0.71 (3.15%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 61
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 1,318
  • Open Int (30-Day) 1,330
  • Expected Range 21.93 to 23.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.56
  • Number of Estimates 1
  • High Estimate $0.56
  • Low Estimate $0.56
  • Prior Year $0.77
  • Growth Rate Est. (year over year) -27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.24 +6.59%
on 06/01/26
23.37 -3.13%
on 06/11/26
+0.67 (+3.05%)
since 05/15/26
3-Month
21.24 +6.59%
on 06/01/26
24.45 -7.40%
on 04/20/26
+0.58 (+2.63%)
since 03/17/26
52-Week
16.52 +37.05%
on 10/15/25
25.15 -9.96%
on 02/26/26
+1.20 (+5.60%)
since 06/17/25

Most Recent Stories

More News
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

Agreement expands access to XACDURO ® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central...

INVA : 22.64 (+0.13%)
Innoviva to Participate in Upcoming Investor Conferences

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known...

INVA : 22.64 (+0.13%)
Innoviva: Q1 Earnings Snapshot

Innoviva: Q1 Earnings Snapshot

INVA : 22.64 (+0.13%)
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Generated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year...

INVA : 22.64 (+0.13%)
Innoviva's Royalty Foundation Meets a Product Portfolio That Finally Carries Its Own Weight

Barchart Research What to Expect from INVA Earnings INVA Generated May 5, 2026 Current Price $22.65 EPS Estimate $$0.43 Consensus Rating Moderate Buy Average Move 3.03% Innoviva's Royalty Foundation Meets...

INVA : 22.64 (+0.13%)
3 Bargain-Cheap Small Caps Worth a Second Look

Three low P/E small-cap stocks offer distinct catalysts and upside potential as investors look ahead to a broader market rally

WEN : 6.95 (+2.66%)
INVA : 22.64 (+0.13%)
GSK : 52.15 (-0.13%)
NBR : 89.15 (-2.25%)
Innoviva: Q4 Earnings Snapshot

Innoviva: Q4 Earnings Snapshot

INVA : 22.64 (+0.13%)
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year IST achieved U.S. net product sales of $33.9...

INVA : 22.64 (+0.13%)
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva...

INVA : 22.64 (+0.13%)
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out

Significant updates from the FDA toward the end of 2025 have rallied investor interest in Axsome and Innoviva, two high-potential biotech names for 2026.

INVA : 22.64 (+0.13%)
AXSM : 252.16 (+0.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance,...

See More

Key Turning Points

3rd Resistance Point 23.37
2nd Resistance Point 23.11
1st Resistance Point 22.88
Last Price 22.64
1st Support Level 22.39
2nd Support Level 22.13
3rd Support Level 21.90

See More

52-Week High 25.15
Last Price 22.64
Fibonacci 61.8% 21.85
Fibonacci 50% 20.83
Fibonacci 38.2% 19.81
52-Week Low 16.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.